Genor Biopharma Holdings (HKSE:06998) ROCE % : -20.43% (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genor Biopharma Holdings's annualized ROCE % for the quarter that ended in Jun. 2024 was -20.43%.

Genor Biopharma Holdings ROCE % Historical Data

The historical data trend for Genor Biopharma Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings ROCE % Chart

Genor Biopharma Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-164.96

-29.95

-31.38

-43.50

-2.89

Genor Biopharma Holdings Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial							-30.99	-31.41	-56.65	-20.43	14.81

Genor Biopharma Holdings ROCE % Calculation

Genor Biopharma Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-740.06	/	( ( (2361.953 - 290.787)	+	(1582.564 - 251.05) )	/ 2 )
	=	-740.06	/	( (2071.166	+	1331.514)	/ 2 )
	=	-740.06	/	1701.34
	=	-43.50 %

Genor Biopharma Holdings's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-255.328	/	( ( (1582.564 - 251.05)	+	(1371.862 - 204.154) )	/ 2 )
	=	-255.328	/	( ( 1331.514	+	1167.708 )	/ 2 )
	=	-255.328	/	1249.611
	=	-20.43 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Genor Biopharma Holdings (HKSE:06998) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Genor Biopharma Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genor Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

67N:Germany

Address

690 Bibo Road, Room 401-17, Building 6, Pudong New District, Shanghai, CHN, 201203

Website

https://www.genorbio.com

Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.

Executives

Forebright New Opportunities Fund, L.p.	2101 Beneficial owner
Forbright Global Limited	2201 Interest of corporation controlled by you
Fnof Gp Limited	2201 Interest of corporation controlled by you
Deg – Deutsche Investitions- Und Entwicklungsgesellschaft Mbh	2101 Beneficial owner
Hsg Growth V Holdco Q, Ltd.	2101 Beneficial owner
Hsg Holding Limited	2201 Interest of corporation controlled by you
Snp China Enterprises Limited	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund Management I, L.p.	2201 Interest of corporation controlled by you
Shen Nan Peng	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund I, L.p.	2101 Beneficial owner
Hongshan Capital Growth Fund V, L.p.	2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p.	2201 Interest of corporation controlled by you
Hongshan Capital Management I, L.p.	2201 Interest of corporation controlled by you
Hongshan Capital I, L.p.	2101 Beneficial owner
Ni Xin	2101 Beneficial owner

Genor Biopharma Holdings Headlines

No Headlines